Original Article
Role of Oral Rifampicin in Chronic Central Serous
Chorioretinopathy
P.S. Mahar, Nasir Memon, A. Sami Memon, M. Faisal Faheem
Pak J Ophthalmol 2018, Vol. 34, No. 1
. . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . .. . .. . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . .
See
end of article for authors
affiliations …..……………………….. Correspondence
to: Prof. P.S
Mahar Isra Postgraduate Institute of
Ophthalmology Karachi,
Pakistan E-mail: salim.mahar@aku.edu |
Purpose: To determine the improvement in
visual acuity and central macular thickness in patients with chronic central
serous chorioretinopathy (CSCR) with oral Rifampicin. Study Design: Quasi experimental study. Place and Duration of Study: Isra
Postgraduate Institute of Ophthalmology, Al-Ibrahim Eye Hospital, Karachi.
From September 2015 to December 2016. Material & Methods: Ten
eyes of 10 patients having chronic CSCR of more than 6 months duration were
prospectively treated with oral Rifampicin 450 mg in single oral dose for 3
months duration. All patients were followed-up for 12 months. Results: Ten eyes of 10 patients were included in
the study. The gender distribution showed 8 male (80%) and 2 female (20%)
patients. There were five right and five left eyes. Mean age of our patients was 40.10 ± 5.1
years (Range Conclusion: All patients with chronic CSCR
of more than 6 months duration showed improvement in their vision and central
macular thickness with oral Rifampicin taken for 3 months. Key Words: Rifampicin, Central serous
chorioretinopathy, Visual acuity, Central macular thickness. |
Central serous chorioretinopathy (CSCR) is
characterized by elevation of neuro sensory retina at the posterior pole. In majority
of the cases, the cause remains unknown so the condition is termed as
idiopathic. CSCR is a self-limiting disease with spontaneous resolution occurring
within 3 – 4 months of initial episode resulting in good visual outcome1.
Observation alone is therefore advised as the first line approach in the newly
diagnosed cases. However, risks factors such as increase stress score, raised homocysteine
and serum cortisol level and elevated systolic blood pressure should be
addressed2. Unfortunately, recurrences are seen in up to 50% of
patients within the first year. In 10 – 20% of cases, patients can have
persistent serous retinal detachment
with progressive decreased vision3.
The exact mechanism of the disease is not
known. Gass suggested that an increase in the choriocapillaris permeability was
the primary cause of damage to the overlying retinal pigment epithelium (RPE),
resulting in accumulation of fluid under the neuro sensory retina4.
This theory has been recently supported by choroidal vessel staining on
indo-cyanine green (ICG) angiography and appearance of thickened choroid on
swept source optical coherence tomography (OCT)5.
CSCR has been associated with intake of
steroids and also described in patients with Cushing disease, pregnancy and
stress with endogenous high level of cortisol secretion6. As
glucocorticoids are implicated in the pathogenesis of CSCR, their inhibition
has been suggested as a potential treatment modality.
There are several options of treatment
described in patients when sub-retinal fluid persists beyond 3 months and
condition takes a chronic course with progressive decrease in vision. The ICG –
guided photodynamic therapy with verteporfen was described by Yannuzi in
patients with chronic CSCR with favorable results7. Intravitreal
anti – vascular endothelial growth factor (VEGF) such as bevacizumab8
and systemic pharmacologic therapy affecting glucocorticoid metabolism has also
been described in chronic CSCR9.
Rifampicin is an anti-tuberculous drug and
is known to induce cytochrome P450 3A4 to alter the metabolism of endogenous
steroids with an improvement in clinical features of CSCR10.
Although the first report of use of Rifampicin
in chronic CSCR is attributed to Ravage and Packo11 for their
presentation during American society of retinal specialist meeting in 2010, the
first reported case in literature is described by Steinle and colleagues
published in British Journal of Ophthalmology (BJO) in 201112.
We carried out a
prospective study to evaluate the efficacy of oral Rifampicin (Rimactal -
Sandoz Pakistan) in patients with chronic CSCR who had persistent sub-retinal
fluid (SRF) for more than 6 months of initial presentation with diminished
vision. The primary outcome measure in our study was decrease in SRF documented
on OCT and secondary outcome was an increase in the Snellen’s visual acuity
after the treatment with Rifampicin for 3 months.
MATERIALS & METHODS
We prospectively treated 10 eyes of 10
patients having chronic CSCR of more than 6 months duration with oral
Rifampicin 450 mg in a single oral dose for 3 months. All patients were
followed up for 12 months duration.
This was quasi experimental study with
non-probability convenience sampling. The study was conducted at Isra
Postgraduate Institute of Ophthalmology, Karachi from September, 2015 till December
2016. The study was approved by the Research Ethical Committee of the Institute
(Protocol No. A-00044).
All patients gave consent for taking
Rifampicin orally. The study patients had detailed history of visual symptoms
with any other significant medical or surgical history with intake of any oral
medication. The ocular examination included best corrected visual acuity (BCVA)
on Snellen’s chart, bio-microscopic examination of anterior segments with
intraocular pressure (IOP) measurement. Every patient underwent dilated fundus
examination with + 90 Diopter lens and subsequently OCT scan of macula (Topcon
– Japan). In some cases fundus fluorescein angiography (FFA) was also obtained.
Once patient was initiated on oral Rifampicin therapy, ocular examination was
repeated at each monthly visit with recording of BCVA. At monthly follow up,
OCT scan was also repeated to demonstrate any change in the presence of SRF with
decrease in central macular thickness (CMT).
All patients with confirmed diagnosis of
CSCR on clinical examination confirmed with OCT scan with age limit of 20 – 50
years were included in the study. Any patient having oral acetazolamide, methotrexate
or history of intravitreal injection of Bevacizumab in last 3 months was
excluded. Patients taking topical non-steroidal anti-inflammatory drugs and
topical carbonic anhydrase inhibitors were also excluded from the study.
Before the start of the
treatment liver function tests (LFTs) and complete blood count (CBC)of all
patients was worked up. These tests were repeated every month while patient was
taking oral Rifampicin. Rifampicin was discontinued after 3 months of
treatment.
Statistical Analysis
Data
analysis was done through the software SPSS version 20.0. All the continuous
variables were presented in Mean and Standard Deviation. The entire categorical
variables were shown in frequency and percentages. Paired sample t test was
used to find the significance between pre and post CMT and Chi square test was
used for categorical variable like Visual Acuity. P value≤0.05
was considered to be statistically significant.
RESULTS
Ten eyes of 10 patients were included in
the study. The gender distribution showed 8 males (80%) and 2 females (20%). there were five left and five right eyes. Mean age was 40.10 ± 5.1 years (Range 34 – 46 years). Mean duration of patient’s ocular
symptoms was 9.4 ± 2.9 months with range of 6 – 14 Months (Table 1).
OCT=
Optical coherence tomography
CMT= Central macular thickness (microns)
Table 1: Demographic Characteristics of
Patients.
The enrolled patients were commenced on
oral Rifampicin (450 mg) half an hour before the breakfast. Patient’s visual
acuity improved at 3 months follow-up (Figure 1).
Mean pre-treatment central macular thickness
(CMT) was 350 ± 82.3 µm
improving to 232 ± 54.3 µm at 3 months treatment (Figure 2).
All patients’ OCT scans showing CMT are
given in figure A. These patients were followed upto 12 months and showed
stable vision.
The drug was very well
tolerated by all the patients for 3 months duration and improvements in visual
acuity and CMT were sustained till 12 months follow-up.
Age, Years |
40.10 ± 5.1 |
Age Range, Years` |
32 – 46 |
Gender |
|
Male |
8 (80%) |
Female |
2 (20%) |
Affected eye |
|
Right |
5 (50%) |
Left |
5 (50%) |
Duration of symptoms (months) |
9.4 ± 2.9 |
*Data presented in Mean± SD &
frequency (%)
P-value = 0.028
*Chi-Square test was
applied to see the significance
*P-value ≤ 0.05
considered to be statistically significant
Fig. 1: Comparison of Visual Acuity.
P-value
= 0.007
Fig. 2: Comparison of Mean Central Macular Thickness (CMT).
DISCUSSION
Chronic CSCR can be a debilitating disease
with decrease in visual acuity due to persistent presence of fluid in the
sub-retinal space and wide spread RPE atrophy. It is associated with higher
recurrence rate and potentially poor visual prognosis. There are multiple
options described in the literature to treat chronic CSCR. This includes
reduced fluence PDT with verteporfin13, transpupillary thermotherapy14,
intravitreal ranibizumab15 and micro-pulse diode laser photocoagulation16.
Jampol and colleagues first suggested that
glaucocorticosteroids antagonist may be of value in treating repeated episodes
of CSCR. This was based on the association of endogenous hypercortisolism with
the development of CSCR17.
The exact role of glucocorticoids in
pathogenesis of CSCR is not known but possible mechanism include increased
capillary fragility and hyper permeability leading to choroidal circulation
decompensation with leakage of fluid in the sub-retinal space18.
Rifampicin is an anti-tuberculous drug with
primary action of inducing cytochrome P450 3A4 which catalyzes the drug
metabolism and synthesis of cholesterol, steroids and lipids19. It
is therefore suggested that induction of cytochrome P450 3A4 increases the
metabolism of endogenous steroids resulting in improvement of CSCR features
with resolution of sub-retinal fluid.
We prospectively treated 10 eyes of 10
patients with the diagnosis of chronic CSCR showing sub-retinal fluid on OCT
scan of more than 6 months duration. All these patients had oral Rifampicin 450
mg in single dosage taken for 3 months. As the drug can be hepatotoxic so all
our patients had LFTs done at baseline and repeated every month till cessation
of drug. As all patients had visual complaints of long duration with presence
of SRF we feel that the resolution of patient’s symptoms with decrease in SRF
and CMT were induced by Rifampicin.
It is important to take previous drug
intake history of patients before commencing them on Rifampicin as it can cause
multiple drug interactions with anti-coagulants, anti-convulsants,
anti-arrythmics, anti-fungal, beta blockers, calcium channel blockers, steroids
and certain antibiotics20.
Nattis and Josephberg has described 3 cases
of chronic CSCR with patients having blurred vision over past couple of years.
All cases showed improvement in their visual acuity and amount of SRF present
on OCT21. Biggest series of Rifampicin treated patients has come
from Israel by Shulman and colleagues where 14 eyes of 12 patients had been
treated with oral Rifampicin in dose of 600 mg/day for 4 months22.
Choudhury and co-workers23 treated 13 patients with chronic CSCR,
though the duration of patient’s symptoms was merely 6 weeks old. Ten of their
patients showed improvement in vision with decrease in CMT after getting
treatment with Rifampicin 600 mg in single dose for 4 weeks. It is not clear
from their work that for how long these patients were followed. Khan et al24
found that central macular thickness was reduced from 494±96 um to 306±50 um after 4 weeks of treatment with 300 mg Rifampicin daily.
The optimal dosage and duration of
Rifampicin in treating chronic CSCR is not known. Our patients received 450
mg/day for 3 months with remarkable improvement in their clinical features. Our
work differ from other studies that we only treated those patients who has CSCR
with visual symptoms of more than 6 months duration and were followed-up for 12
months.
As the drug is hepatotoxic and can cause
interaction with other drug, proper medical history and LFTs at baseline and
follow up are mandatory.
Although CSCR is self-limiting disease but
persistence of symptoms with presence of SRF beyond 3 – 4 months warrants
treatment.
Photodynamic therapy (PDT) with verteporfin
with reduced fluence and half exposure time is suggested as the first line
treatment. However, this can be associated with pigmentary changes, RPE
atrophy, RPE tear, choroidal ischemia and secondary choroidal
neovascularization25. Focal argon laser therapy is another option
when leakage occurs outside foveal avascular zone. But these cases can also be
complicated by secondary choroidal neovascularization.
Rifampicin appears
promising, cost-effective and efficacious mode of treatment in chronic CSCR. It
will be interesting also to explore its value in acute cases where prompt
visual recovery is required in patients such as in pilots and doctors.
CONCLUSION
In this study all
patients with chronic CSCR of more than 6 months duration showed improvement in
their visual acuity and corresponding decrease in central macular thickness on
OCT, when treated with oral Rifampicin 450 mg in single dose for 3 months
period.
Author’s
Affiliation
Dr. PS Mahar
FRCS, DO, FRCOphth
Professor & Dean,
Isra Postgraduate Institute of
Ophthalmology,
Karachi.
Dr. Nasir Memon
FCPS, Senior Registrar
Isra Postgraduate Institute of
Ophthalmology,
Karachi.
Dr. A. Sami Memon
MD, FCPS, Assistant Professor
Isra Postgraduate Institute of
Ophthalmology,
Karachi.
Mr. M. Faisal Faheem
MSc (Statistics), Statistician
Isra Postgraduate Institute of
Ophthalmology
Karachi.
Role of
Authors
Dr. PS Mahar
Writing the manuscript.
Nasir Memon
Collection of data.
A. Sami Memon
Collection of data.
M. Faisal Faheem
REFERENCES
1.
Marmor MF. New
hypotheses on the pathogenesis and treatment of serous retinal detachment.
Graefes Arch Clin Exp Ophthalmol. 1988; 226: 548-52.
2.
Agarwal A, Garg M, Dixit N, Godara R. Evaluation and correlation of stress scores with blood pressure,
endogenous cortisol levels, and homocysteine levels in patients with central
serous chorioretinopathy and comparison with age-matched controls. Indian J
Ophthalmol. 2016; 64: 803-5.
3.
Spaide RF, Goldbaum M, Wong DWK, et al. Serous detachment of the retina. Retina. 2003; 23: 820-46.
4.
Gass JDM.
Pathogenesis of disciform detachment of the neuroepithelium: V. Disciform
macular detachment secondary to focal choroiditis. Am J Ophthalmol. 1967; 63: 661-87.
5.
Spaide RF, Koizumi H, Pozzoni MC. Enhanced depth imaging spectral-domain optical coherence tomography.
Am J Ophthalmol. 2008; 146: 496-500.
6.
Sharma T, Shah N, Rao M, et al. Visual outcome after discontinuation of corticosteroids in
atypical severe central serous choriorretinopathy. Ophthalmology, 2004; 111: 1708-14.
7.
Yannuzzi LA.
Chronic central serous and fundus autofluorescence. Retinal Cases and Brief
Reports, 2008; 2: 1-5.
8.
Huang WC, Chen WL, Tsai YY, Chiang CC, Lin JM. Intravitreal bevacizumab for treatment of chronic central serous
chorioretinopathy. Eye, 2009; 23 (2): 488-9.
9.
Meyerle CB, Freund KB, Bhatnagar P, Shah V, Yannuzzi LA et al. Ketoconazole in the treatment of chronic idiopathic central
serous chorioretinopathy. Retina, 2007; 27: 943-6.
10.
Wang M, Munch IC, Hasler PW et al. Central serous chorioretinopathy. Acta Ophthalmol. 2008; 86: 126-45.
11.
Ravage Z, Packo K.
Rifampicin for treatment of central serous chorioretinopathy. Invest Ophthalmol
Vis Sci. 2011; 52: ARVO E-Abstract 2137.
12.
Steinle N, Gupta N, Yuan A, Singh R. Oral rifampicin utilization for the treatment of chronic
multifocal central serous retinopathy. Br J Ophthalmol. 2011; 96: 10-3.
13.
Shin JY, Woo SJ, Yu SG, et al. Comparison of efficacy and safety between half-fluence and
full-fluence photodynamic therapy for chronic central serous chorioretinopathy.
Retina. 2011; 31: 119-26.
14.
Shukla D, Kolluru C, Vignesh TP et al. Transpupillary thermotherapy for subfoveal leaks in central
serous chorioretinopathy. Eye, 2006; 22: 100-6.
15.
Bae SH, Heo JW, Kim C, et al. Randomized pilot study of low-fluence photodynamic therapy versus
intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J
Ophthalmol. 2011; 152: 784-92.
16.
Sivaprasad S, Elagonz M, McHugh D, et al. Micropulsed diode laser therapy: evolution and clinical
applications. Surv Ophthalmol. 2010; 55: 516-30.
17.
Jampol LM, Weinreb R, Yannuzzi LA. Involvement of corticosteroids and catecholamines in the
pathogenesis of central serous chorioretinopathy: a rationale for new treatment
strategies. Ophthalmology, 2002; 109: 1765-6.
18.
Garg SP, Dada T, Talwar D, et al. Endogenous cortisol profile in patients with central serous
chorioretinopathy. Br J Ophthalmol. 1997; 81: 962-4.
19.
Guengerich FP.
Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev
Pharmacol Toxicol. 1999; 39: 1-17.
20.
Finch CK, Chrisman CR, Baciewicz AM, Self TH. Rifampicin and rifabutin drug interactions: an update. Arch Intern
Med. 2002; 162 (9): 985-92.
21.
Nattis A, Josephberg R. Rifampin as an efficacious therapy for chronic CSC. Retinal
Physician, 2015; 12: 52-7.
22.
Shulman S, Goldenberg
D, Schwartz R, Habot-Wilner Z, Barak A, Ehrlich N, Loewenstein A, Goldstein M. Oral Rifampin
treatment for longstanding chronic central serous chorioretinopathy. Graefe's
Archive for Clinical and Experimental Ophthalmology. 2016; 254(1):15-22.
23.
Choudhury D, Sharma P,
Dora J. Role of Rifampicin and Ketoconazole in Chronic
Central Serous Chorioretinopathy & 58; a Comparative Study. Journal of
Evidence Based Medicine and Healthcare, 2016; 3 (72): 3940-4.
24.
Khan MS, Sameen M,
Lodhi AA, Ahmed M, Ahmed N, Kamal M, Junejo SA. Effect of half adult dose of oral
Rifampicin (300mg) in patients with idiopathic central serous
chorioretinopathy. Pakistan journal of medical sciences. 2016 Sep;32(5):1158.
25.
Kim SW, Oh J, Oh IK, Huh K.
Retinal pigment epithelial tear after half fluence PDT for serous pigment
epithelial detachment in central serous chorioretinopathy. Ophthalmic Surg
Lasers Imaging, 2009; 40: 300-303.